We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

437 hedge funds and large institutions have $6.5B invested in Bio-Rad Laboratories Class A in 2024 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 133 increasing their positions, 169 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $6.56M | Put options by funds: $4.64M

20% more capital invested

Capital invested by funds: $5.41B → $6.5B (+$1.09B)

0.72% more ownership

Funds ownership: 84.5%85.21% (+0.72%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 68

0% less funds holding

Funds holding: 439437 (-2)

21% less repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 169

Holders
437
Holders Change
-2
Holders Change %
-0.46%
% of All Funds
6.28%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
68
Increased
133
Reduced
169
Closed
68
Calls
$6.56M
Puts
$4.64M
Net Calls
+$1.91M
Net Calls Change
+$8.17M
Name Holding Trade Value Shares
Change
Change in
Stake
Charles Schwab
26
Charles Schwab
California
$61.7M -$14.7M -46,341 -20%
FPA
27
First Pacific Advisors
California
$52.8M -$850K -2,675 -2%
DM
28
Deerfield Management
New York
$50.7M -$44.1K -139 -0.1%
Artisan Partners
29
Artisan Partners
Wisconsin
$49.9M -$2.74M -8,616 -5%
Allspring Global Investments
30
Allspring Global Investments
North Carolina
$49.8M -$2.44M -7,691 -5%
GKIM
31
GW&K Investment Management
Massachusetts
$48.6M +$1.39M +4,391 +3%
QM
32
QVIDTVM Management
Texas
$42.1M
Federated Hermes
33
Federated Hermes
Pennsylvania
$40.6M +$8.51M +26,787 +28%
Franklin Resources
34
Franklin Resources
California
$40M -$1.1M -3,469 -3%
TM
35
Tikvah Management
North Carolina
$39.5M
Envestnet Asset Management
36
Envestnet Asset Management
Illinois
$33M -$3.27M -10,311 -9%
ACA
37
Anchor Capital Advisors
Massachusetts
$32.7M +$3.87M +12,190 +14%
Fisher Asset Management
38
Fisher Asset Management
Washington
$31M -$281K -886 -0.9%
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$29M +$7.64M +24,052 +38%
Grantham, Mayo, Van Otterloo & Co (GMO)
40
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$27.7M -$4.23M -13,334 -14%
Goldman Sachs
41
Goldman Sachs
New York
$26M -$18.2M -57,160 -42%
MAMU
42
Marathon Asset Management (UK)
United Kingdom
$23.9M +$109K +344 +0.5%
HP
43
Hound Partners
New York
$22.9M -$30.7M -96,510 -59%
Legal & General Group
44
Legal & General Group
United Kingdom
$22.3M -$12.9M -40,706 -38%
HP
45
Hosking Partners
United Kingdom
$20.8M -$939K -2,956 -5%
PCM
46
Philosophy Capital Management
California
$19.8M +$755K +2,378 +4%
Swiss National Bank
47
Swiss National Bank
Switzerland
$19.8M +$127K +400 +0.7%
DC
48
Davenport & Co
Virginia
$19M +$187K +590 +1%
Comerica Bank
49
Comerica Bank
Texas
$18.5M +$2.92M +9,197 +20%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$18.1M +$6.15M +19,373 +56%

BIO Hedge Fund Activity: Q3 2024 in Review

437 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q3 2024, worth a combined $6.5B — up 20% from $5.41B a quarter earlier.

Fund positioning in BIO was balanced in Q3 2024: 68 funds opened new positions, 68 closed out, 133 added to existing stakes and 169 trimmed.

The largest buyer was VanEck Associates, adding an estimated $205M. The largest seller was Invesco, cutting an estimated $161M.

  • 437 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q3 2024, down from 439 in Q2 2024.
  • Funds reported $6.5B of Bio-Rad Laboratories Class A stock for Q3 2024, up 20% quarter-over-quarter.
  • 68 funds opened new Bio-Rad Laboratories Class A positions in Q3 2024 and 68 closed out, a net change of 0 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q3 2024 was VanEck Associates, an estimated $205M added.
  • The largest Bio-Rad Laboratories Class A seller in Q3 2024 was Invesco, an estimated $161M sold.

Based on aggregated 13F filings for Q3 2024.